Zenas BioPharma (NASDAQ:ZBIO) Director Purchases $584,662.50 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Hongbo Lu purchased 25,985 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were bought at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the acquisition, the director directly owned 347,968 shares in the company, valued at $7,829,280. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Zenas BioPharma Stock Up 1.1%

NASDAQ ZBIO opened at $26.40 on Monday. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. Zenas BioPharma, Inc. has a 52 week low of $6.11 and a 52 week high of $44.60. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.47. The company has a fifty day moving average of $27.56 and a two-hundred day moving average of $25.72.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. Marshall Wace LLP bought a new position in Zenas BioPharma in the fourth quarter worth approximately $258,000. The Manufacturers Life Insurance Company purchased a new position in shares of Zenas BioPharma in the 4th quarter valued at $227,000. Charles Schwab Investment Management Inc. raised its position in shares of Zenas BioPharma by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 213,193 shares of the company’s stock worth $7,741,000 after acquiring an additional 34,797 shares in the last quarter. State Street Corp lifted its stake in shares of Zenas BioPharma by 16.1% during the 4th quarter. State Street Corp now owns 438,294 shares of the company’s stock worth $15,914,000 after purchasing an additional 60,809 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Zenas BioPharma during the fourth quarter valued at about $305,000.

Analyst Ratings Changes

A number of research firms have weighed in on ZBIO. HC Wainwright reiterated a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a research note on Tuesday, February 10th. Citigroup upped their target price on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Finally, Wall Street Zen lowered Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.